Recurrent Squamous Cell Carcinoma of the Hypopharynx Completed Phase 1 Trials for Filgrastim (DB00099)

IndicationStatusPhase
DBCOND0029504 (Recurrent Squamous Cell Carcinoma of the Hypopharynx)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00023959Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerTreatment